The Board of Directors of J.B. Chemicals & Pharmaceuticals has approved the unaudited financial results for Q2 2026, ending September 30, 2025. Key highlights include revenue from operations of ₹1,022.65 million and a net profit after tax of ₹200.42 million. The Board has also approved related party transactions for the half-year ended September 30, 2025.
Financial Performance
J.B. Chemicals & Pharmaceuticals has announced its financial results for the second quarter of fiscal year 2026. Here’s a snapshot of their standalone performance:
Revenue from operations stood at ₹1,022.65 million for the quarter ended September 30, 2025, compared to ₹955.76 million for the corresponding quarter last year.
Net profit after tax reached ₹200.42 million for the quarter.
For the half-year ended September 30, 2025, the company reported total revenue of ₹2,062.55 million and net profit after tax of ₹398.29 million.
Key Highlights
The Board of Directors approved the unaudited standalone and consolidated financial results for Q2 2026.
The company reported earnings per share of ₹12.82 for the quarter.
Changes in Shareholding
An increase in the paid-up equity share capital was noted during the quarter ended September 30, 2025, resulting from the allotment of equity shares pursuant to the ESOS scheme.
Acquisition Approval
The Competition Commission of India (CCI) has approved the acquisition of the company by Torrent Pharmaceuticals Limited, subject to certain modifications.
Related Party Transactions
The Board approved related party transactions for the half-year ended September 30, 2025, with detailed disclosures provided.
Source: BSE
